Zogenix to Announce New Data at American Epilepsy Society

Full Results from Second Pivotal Phase 3 Trial of FINTEPLA^® (ZX008) in Dravet Syndrome (Study 1504)

New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503)

Studies on the Impact of Severe Epilepsy on Quality of Life for Patients and Families

 Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that data from nine abstracts, including four “late-breakers,” will be presented at the 72^nd American Epilepsy Society (AES) Annual Meeting taking place in New Orleans from November 30 – December 4, 2018. The Zogenix-sponsored presentations will include new clinical data from the second pivotal Phase 3 study, data on the long-term efficacy and safety of FINTEPLA^® (ZX008) in Dravet syndrome, along with data further demonstrating the significant burden that living with severe childhood onset epilepsy has on children, caregivers and family members.

In addition to the posters, Zogenix will host a Scientific Exhibit Room on Sunday, December 2 from 8:00 am – 11:00 am CT. Zogenix study investigators and authors will be present to discuss the posters in more detail and answer questions.

https://www.marketscreener.com/ZOGENIX-INC-22779450/news/Zogenix-to-Announce-New-Data-at-72nd-American-Epilepsy-Society-Annual-Meeting-27661558/